This database contains 1433 studies, archived under the term: ""
Click here to filter this large number of results.
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline
Grundman, Michael,
Pontecorvo, Michael J.,
Salloway, Stephen P.,
Doraiswamy, P. Murali,
Fleisher, Adam S.,
Sadowsky, Carl H.,
Nair, Anil K.,
Siderowf, Andrew,
Lu, Ming,
Arora, Anupa K.,
Agbulos, Abigail,
Flitter, Matthew L.,
Krautkramer, Michael J.,
Sarsour, Khaled,
Skovronsky, Daniel M.,
Mintun, Mark A.
Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to […]
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease
Grove, Richard A.,
Harrington, Conn M.,
Mahler, Andreas,
Beresford, Isabel,
Maruff, Paul,
Lowy, Martin T.,
Nicholls, Andrew P.,
Boardley, Rebecca L.,
Berges, Alienor C.,
Nathan, Pradeep J.,
Horrigan, Joseph P.
Introduction: Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treatment for subjects with mild-to-moderate probable Alzheimer’s disease (AD).; Methods: In this 16-week, double-blind, randomized, parallel group study, 196 currently […]
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors
Grossberg, George T.,
Manes, Facundo,
Allegri, Ricardo F.,
Gutiérrez-Robledo, Luis Miguel,
Gloger, Sergio,
Xie, Lei,
Jia, X. Daniel,
Pejović, Vojislav,
Miller, Michael L.,
Perhach, James L.,
Graham, Stephen M.
Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors.; Methods: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of […]
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease
Grossberg, G.,
Cummings, J.,
Frolich, L.,
Bellelli, G.,
Molinuevo, J. L.,
Krahnke, T.,
Strohmaier, C.
Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]
A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects
Grimaldi, Luigi Maria,
Zappalà, Giuseppe,
Iemolo, Francesco,
Castellano, Anna,
Ruggieri, Stefano,
Bruno, Giuseppe,
Paolillo, Andrea
Despite the fact that multiple sclerosis (MS) and Alzheimer’s disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in […]
Robot services for elderly with cognitive impairment: testing usability of graphical user interfaces
Granata, C.,
Pino, M.,
Legouverneur, G.,
Vidal, J. S.,
Bidaud, P.,
Rigaud, A. S.
Background: Socially assistive robotics for elderly care is a growing field. However, although robotics has the potential to support elderly in daily tasks by offering specific services, the development of usable interfaces is still a challenge. Since several factors such as age or disease-related changes in perceptual or cognitive abilities and familiarity with computer technologies […]
Semantic memory training in Alzheimer’s disease
The purpose of this study was to assess the effects of semantic stimulation of Alzheimer’s patients on semantic memory comparatively to psychological support. We conducted semantic training with two target categories (musical instruments and human actions), because these concepts were massively failed in previous data collected in Alzheimer’s disease. Ten patients (57-78 year old, MMSE […]
Telephone-based, cognitive-behavioral therapy for African American dementia caregivers with depression: initial findings
Glueckauf, Robert L.,
Davis, W. Shuford,
Willis, Floyd,
Sharma, Dinesh,
Gustafson, David J.,
Hayes, Jocelyn,
Stutzman, Mary,
Proctor, James,
Kazmer, Michelle M.,
Murray, Leticia,
Shipman, Judith,
McIntyre, Vera,
Wesley, Lonnie,
Schettini, Gabriel,
Xu, Jian,
Parfitt, Francine,
Graff-Radford, Neill,
Baxter, Cynthia,
Burnett, Kathleen,
Noël, La Tonya,
Haire, Kambria,
Springer, Jane
Objectives: Discuss initial findings of a randomized clinical trial comparing the effects of telephone-based and face-to-face (f-to-f) cognitive-behavioral therapy (CBT) on changes in caregiver (CG) burden, assistance support, depression, and health status for African American (AA) CGs with depression.; Design: Pilot study using a prepost, two-group design with 14 enrolled and randomized participants.; Measures: Subjective […]